|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 1999; 33:1400-1407 © 1999 by the American College of Cardiology Foundation |
a Department of Cardiovascular Medicine, Kyoto University, Kyoto, Japan
Manuscript received June 22, 1998; revised manuscript received November 5, 1998, accepted December 22, 1998.
Reprint requests and correspondence: Dr. Akira Matsumori, Department of Cardiovascular Medicine, Kyoto University, 54 Kawaracho, Shogoin, Sakyo-ku, Kyoto 606-8397, Japan.
amat{at}kuhp.kyoto-u.ac.jp
OBJECTIVES
This study was designed to examine the effects of pimobendan in a murine model of viral myocarditis in relation to proinflammatory cytokine production and nitric oxide (NO) synthesis by inducible NO synthase (iNOS) in the heart.
BACKGROUND
Pimobendan has been recently confirmed to improve both acute and chronic heart failure. Since the modulation of myocardial necrosis and contractile dysfunction by various proinflammatory cytokines may be partially mediated by the production of nitric oxide, the effects of pimobendan on the production of proinflammatory cytokines and NO were investigated in an animal model of viral myocarditis involving heart failure.
METHODS
DBA/2 mice were inoculated with the encephalomyocarditis virus. To observe its effect on survival up to 14 days, pimobendan (0.1 mg/kg or 1 mg/kg) or vehicles were given from the day of virus inoculation (day 0) orally once daily. The effects of pimobendan on histological changes, cytokine production, NO production and iNOS gene expression in the heart were studied in mice treated either with pimobendan, 1 mg/kg or with vehicles only, and sacrificed seven days after virus inoculation.
RESULTS
The survival of mice improved in a dose-dependent fashion such that a significant difference (p < 0.02) was found between the higher-dose pimobendan group (20 of 30 [66.7%]) and the control group (11 of 30 [36.7%]). Histological scores for cellular infiltration (1.1 ± 0.1 vs. 2.0 ± 0.0, p < 0.001), intracardiac tumor necrosis factor (TNF)-
(18.2 ± 1.8 vs. 35.8 ± 4.2 pg/mg heart, p < 0.001) and interleukin (IL)-1ß (9.3 ± 1.2 vs. 26.6 ± 7.1 pg/mg heart, p < 0.01) were significantly lower in the mice given pimobendan versus those of the control mice. Interleukin-6 levels (7.1 ± 0.8 vs. 9.2 ± 1.9 pg/mg heart) were also lower in the mice treated with pimobendan. Furthermore, intracardiac NO production was significantly (p < 0.001) less in the pimobendan group (0.165 ± 0.004 nmol/mg heart) than in the control group (0.291 ± 0.051 nmol/mg heart), and intracardiac iNOS gene expression in the mice given pimobendan was 74% lower than it was in the control animals (p < 0.01).
CONCLUSIONS
These findings suggest that the beneficial effects of pimobendan in viral myocarditis are partially mediated by the inhibition of both proinflammatory cytokine production and NO synthesis by iNOS.
| ||||||||||||||||||||
This article has been cited by other articles:
|
|
 |
|
  A. R. Hemnes, A. Zaiman, and H. C. Champion PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation Am J Physiol Lung Cell Mol Physiol, January 1, 2008; 294(1): L24 - L33. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. W. Lombard, O. Jons, and C. M. Bussadori Clinical Efficacy of Pimobendan Versus Benazepril for the Treatment of Acquired Atrioventricular Valvular Disease in Dogs J. Am. Anim. Hosp. Assoc., July 1, 2006; 42(4): 249 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Gordon, M. W. Miller, and A. B. Saunders Pimobendan in Heart Failure Therapy - A Silver Bullet? J. Am. Anim. Hosp. Assoc., March 1, 2006; 42(2): 90 - 93. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Yamamoto, T. Shioi, K. Uchiyama, T. Miyamoto, S. Sasayama, and A. Matsumori Attenuation of virus-induced myocardial injury by inhibition of the angiotensin II type 1 receptor signal and decreased nuclear factor-kappa B activation in knockout mice J. Am. Coll. Cardiol., December 3, 2003; 42(11): 2000 - 2006. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Matsumori Cytokines in myocarditis and dilated cardiomyopathy Eur. Heart J. Suppl., December 1, 2002; 4(suppl_I): I42 - I45. [Abstract] [PDF]
|
|
|
|
|
|
Y. Ishibashi, T. Shimada, Y. Murakami, N. Takahashi, T. Sakane, T. Sugamori, S. Ohata, S.-i. Inoue, Y. Ohta, K. Nakamura, et al. An inhibitor of inducible nitric oxide synthase decreases forearm blood flow in patients with congestive heart failure J. Am. Coll. Cardiol., November 1, 2001; 38(5): 1470 - 1476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Miyamoto, A. Matsumori, M.-W. Hwang, R. Nishio, H. Ito, and S. Sasayama Therapeutic effects of FTY720, a new immunosuppressive agent, in a murine model of acute viral myocarditis J. Am. Coll. Cardiol., May 1, 2001; 37(6): 1713 - 1718. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Feldman and D. McNamara Myocarditis N. Engl. J. Med., November 9, 2000; 343(19): 1388 - 1398. [Full Text] [PDF]
|
|
|
|
|
|
J. S. Karliner Fulminant Myocarditis N. Engl. J. Med., March 9, 2000; 342(10): 734 - 735. [Full Text]
|
|
|
|
 |
|
 S. A. Huber T cells expressing the {gamma}{delta} T cell receptor induce apoptosis in cardiac myocytes Cardiovasc Res, February 1, 2000; 45(3): 579 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Iordanov, J. M. Paranjape, A. Zhou, J. Wong, B. R. G. Williams, E. F. Meurs, R. H. Silverman, and B. E. Magun Activation of p38 Mitogen-Activated Protein Kinase and c-Jun NH2-Terminal Kinase by Double-Stranded RNA and Encephalomyocarditis Virus: Involvement of RNase L, Protein Kinase R, and Alternative Pathways Mol. Cell. Biol., January 15, 2000; 20(2): 617 - 627. [Abstract] [Full Text]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
